Plerixafor Medicine 07 December 2022 Extended indication Multiple Myeloma; Hematopoietic Stem Cell Transplantation Therapeutic value Possible equal value Total cost Registration phase Registered Product Active substance Plerixafor Domain Hematology Reason of inclusion Generic G Main indication Stem cell transplants Extended indication Multiple Myeloma; Hematopoietic Stem Cell Transplantation Current proprietary name Mozobil (Genzyme) Already available biosimilars / generics geen Proprietary name Plerixafor Accord Manufacturer Accord Healthcare Portfolio holder Mechanism of action Receptor antagonist Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Alpha chemokine receptor CXCR4 antagonist. Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date 2021 Expected Registration February 2023 Orphan drug No Registration phase Registered Reimbursement Medicine sluice Additional remarks Positieve opinie in oktober 2022. SPC van het originele product verloopt per 3 augustus 2024. Therapeutic value Current treatment options Therapeutic value Possible equal value This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks